Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2626 to 2640 of 8952 results

  1. Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

    In development Reference number: GID-TA10752 Expected publication date:  08 October 2026

    Technology appraisal guidance
    In development

  2. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

    In development Reference number: GID-TA11674 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  3. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  07 May 2026

    Technology appraisal guidance
    Awaiting development

  4. Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]

    In development Reference number: GID-TA11298 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Allo-APZ2-EB for treating dystrophic and junctional epidermolysis bullosa in people of any age [ID6746]

    Awaiting development Reference number: GID-TA11980 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]

    Awaiting development Reference number: GID-TA11700 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]

    Awaiting development Reference number: GID-TA11784 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]

    In development Reference number: GID-TA11230 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development

  9. Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    In development Reference number: GID-TA11633 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development

  10. Bepirovirsen for treating chronic hepatitis B [ID6608]

    In development Reference number: GID-TA11803 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTE10069 Expected publication date:  11 August 2026

    Health technology evaluations
    In development

  12. Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]

    In development Reference number: GID-TA11576 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development

  13. Amlitelimab for treating moderate to severe atopic dermatitis in people 12 years and over [TSID12394]

    Awaiting development Reference number: GID-TA12005 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Crovalimab for treating atypical haemolytic uraemic syndrome [TSID12386]

    Awaiting development Reference number: GID-TA12006 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [TSID12375]

    Awaiting development Reference number: GID-TA12003 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development